

4-25-05

PCT

JC07 Rec'd PCT/PTO 21 APR 2005

Please type status sign (+) inside this box: →



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/519,128
		Filing Date	Not yet assigned
		First Named Inventor	LEE, RANDALL J.
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Total Number of Pages in This Submission	8	Attorney Docket Number	UCAL-253US1
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement SB08A form <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): POSTCARD	Remarks
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36,513 BOZICEVIC, FIELD & FRANCIS, LLP		
Signature			
Date	April 21, 2005		

EXPRESS MAIL LABEL NO. EV577672655US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV577672655US

INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	UCAL-253US1
	First Named Inventor	LEE, RANDALL J.
	Application Number	10/519,128
	Confirmation No.	Not yet assigned
	Filing Date	Not yet assigned
	Group Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
	Title:	"METHODS AND COMPOSITIONS FOR CORRECTION OF CARDIAC CONDUCTION DISTURBANCES"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


All of the references identified herein were disclosed in a related application serial number 10/291,202 filed 11/7/2002 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. UCAL-253US1 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: April 21, 2005

By: 
Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Please type a plus sign (+) inside this

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

6

Complete if Known

Application Number	10/519,128
Filing Date	Not yet assigned
First Named Inventor	LEE, RANDALL J.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	UCAL-253US1

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,130,141		Law, et al.	07-14-1992	
		6,059,726		Lee, et al.	05-09-2000	
		6,151,525		Soykan, et al.	11-21-2000	
		6,238,429		Markowitz, et al.	05-29-2001	
		6,239,117		Christ, et al.	05-29-2001	
		2001/0009986		Ponzi	07-26-2001	
		2002/0013615		Haim, et al.	01-31-2002	
		2002/0031501		Law	03-14-2002	
		6,387,369		Pittenger, et al.	05-14-2002	
		2002/0061295		Field	05-23-2002	
		2002/0061587		Anversa	05-23-2002	
		6,271,211		Christ et al.	08-07-2001	
		6,415,178		Ben-Haim, et al.	07-02-2002	
		US 2002/0001577		Haverich et al.	01-03-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
			WO 96/18303		Law	06-20-1996		
			WO 98/02150		Stokes, et al.	01-22-1998		
			WO 01/68814		Field	09-20-2001		
			WO 03/094855		The Regents of the University of California & Rhythm Therapeutics Corp	11-20-2003		
			WO 03/095016		The Regents of the University of California	11-20-2003		
			WO 2004/050013		The Regents of the University of California	06-17-2004		

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

6

Complete if Known

Application Number	10/519,128
Filing Date	Not yet assigned
First Named Inventor	LEE, RANDALL J.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	UCAL-253US1

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		American Heart Association. "2001 Heart and Stroke Statistical Update", Dallas, TX: American Heart Association, 1999.	
		ATKINS, et al. "Cellular cardiomyoplasty improves diastolic properties of injured heart", <i>J. Surg. Res.</i> , (1999) Vol. 85: 234-242.	
		ATKINS, et. al. "Myogenic cell transplantation improves <i>in vivo</i> regional performance in infarcted rabbit myocardium" <i>Cardiac and Vascular Regeneration</i> , (2000) Vol. 1: 43-53.	
		ATKINS, et al. Cardiomyoplasty improves diastolic function in a rabbit model of myocardial injury", <i>Circulation</i> , (1998) Vol. 98: Supplement 1: 1227.	
		ATKINS, et. al. "Intracardiac transplantation of skeletal myoblasts yields two populations of striated cells <i>in situ</i> ", <i>Ann Thorac Surg</i> , (1999) Vol. 67: 124-129.	
		ATKINS, et al. "Differential effects of cellular cardiomyoplasty on systolic and diastolic performance in cryoinjured rabbit heart", <i>J Heart Lung Transpl.</i> , (1999) Vol. 18: 43.	
		ATKINS, et al. "Transplanted autologous skeletal myoblasts improve myocardial performance after coronary artery ligation", <i>Cardiac and Vascular Regeneration</i> , (2000) Vol. 1: 76-84.	
		BALOGH, et al. "Expression of gap junction in cultured rat L6 cells during myogenesis", <i>Developmental Biology</i> , (1993) Vol. 155: 351-360.	
		BLAU. "Muscling in on gene therapy", <i>Nature</i> , (1993) Vol. 364: 673-675.	
		BLAU, et al. "Myoblasts in pattern formation and gene therapy", <i>Trends in Genetics</i> , (1993) Vol. 9(8): 269-274.	
		BRITTEBERG, et al. "Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation", <i>The New England J of Med.</i> , (1994) Vol. 331: 889-895.	
		Chachques, et al., "Cellular Therapy Reverses Myocardial Dysfunction" 1st Virtual Congress of Cardiology. The American Association of Thoracic Surgery (Abst) 2000:202	
		CHIU. "Cardiac cell transplantation: The autologous skeletal myoblast implantation for myocardial regeneration", <i>Adv Card Surg</i> , (1999) Vol. 11: 69-98.	
		CHIU, et al. "Cellular cardiomyoplasty: Myocardial regeneration with satellite cell implantation", <i>Ann Thorac Surg</i> , (1995) Vol. 60: 12-18.	
		DAHL, et al. "Expression of gap junction genes, connexin40 and connexin43, during fetal mouse development", <i>Anat. Embryol.</i> , (1995) Vol. 191: 267-278.	
		DAI, et al. "Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation <i>in vivo</i> ", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89: 10892-10895.	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/519,128
		Filing Date	Not yet assigned
		First Named Inventor	LEE, RANDALL J.
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet	3	of	6
		Attorney Docket Number	UCAL-253US1


		Davis, et al., "Modulation of connexin43 expression: effects on cellular coupling", <i>Journal of Cardiovascular Electrophysiology</i> , 1995, vol. 6, no. 2, pgs 103-114	
		DHAWAN, et al. "Systemic delivery of human growth hormone by injection of genetically engineered myoblasts", <i>Science</i> , (1991) Vol. 254: 1509-1512;	
		DOROZYNSKI. "Transplanted cells revive heart muscle", <i>British Medical Journal</i> , (2000) Vol. 321(Issue 7268): 1040-1041.	
		EL OAKLEY, et al. "Myocyte transplantation for myocardial repair: A few good cells can mend a broken heart", <i>Ann Thorac Surg.</i> (2001) Vol. 71(5): 1724-1733.	
		First ever transplantation of skeletal muscle cells to test whether the cells can repair damaged heart muscle. PR Newswire 9/25/00. http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-25-2000/0001321663&EDATE=	
		Field, et al., "Electrophysiological Modulation of Cardiomyocytic Tissue by Transfected Fibroblasts Expressing Potassium Channels" <i>Circulation</i> . 105:522-529 (2002)	
		GAGE, et al. "Genetically modified cells: Applications for intracerebral grafting", <i>Trends in Neuroscience</i> , (1991) Vol. 14(8): 328-333.	
		GenBank Accession No. AA511201	
		GenBank Accession No. AA530689	
		GenBank Accession No. AA822279	
		GenBank Accession No. AA855990	
		GenBank Accession No. AF151980	
		GenBank Accession No. AH003191	
		GenBank Accession No. M61896	
		GenBank Accession No. M65188	
		GenBank Accession No. N86403	
		GenBank Accession No. NM 000165	
		GenBank Accession No. NM 010288	
		GenBank Accession No. NM 012567	
		GenBank Accession No. X61576	
		GenBank Accession No. X62836	
		GUSSONI, et al. "Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation", <i>Nature</i> , (1992) Vol. 356: 435-438.	
		HUSTEN. "Global epidemic of cardiovascular disease predicted", <i>Lancet</i> , (1998) Vol. 352: 1530.	
		JANUS, et al. "The modernization of Asia: Implications for coronary heart disease", <i>Circulation</i> , (1996) Vol. 94: 2671-2673.	
		KAO, et al. "Satellite cell transplantation to repair injured myocardium", <i>Cardiac and Vascular Regeneration</i> , (2000) Vol. 1: 31-42.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/519,128		
		Filing Date	Not yet assigned		
		First Named Inventor	LEE, RANDALL J.		
		Group Art Unit	Not yet assigned		
		Examiner Name	Not yet assigned		
Sheet	4	of	6	Attorney Docket Number	UCAL-253US1


	KESSLER, et al. "Myoblast cell grafting into heart muscle: Cellular biology and potential applications", <i>Annu Rev Physiol</i> , (1999) Vol. 61: 219-242.	
	KNUDSEN, et al. "A role for the Ca ²⁺ -dependent adhesion molecule, N-cadherin, in myoblast interaction during myogenesis", <i>Exp. Cell Res.</i> , (1990) Vol. 188: 175-184.	
	KOUTOUZIS, et al. "Cell transplantation for central nervous system disorders", <i>Critical Reviews in Neurobio.</i> , (1994) Vol. 8(3): 125-162.	
	KHURANA et al. Gene Therapy For Cardiovascular Disease. A Case for Cautious Optimis. <i>Hypertension</i> 2001, Vol. 38, pages 1210-1216	
	LAW, et al. "Cell transplantation as an experimental treatment for Duchenne muscular dystrophy", <i>Transplantation</i> , (1993) Vol. 2: 485-505.	
	LEE, et al. "Coupling requirements for successful impulse propagation with skeletal myocytes transplanted in myocardium", <i>Annals of Biomedical Engineering</i> , (2000) Vol. 28(Supp 1): S54: T6.10.	
	Long, et al., "The Cardiac Fibroblast, Another Therapeutic target for Mending the Broken Heart" <i>J. Mol Cell Cardiol.</i> 34; 1273-1278 (2002).	
	MACCALMAN, et al. "Noncoordinate developmental regulation of N-cadherin, N-CAM, integrin, and fibronectin mRNA levels during myoblast terminal differentiation", <i>Developmental Dynamics</i> , (1992) Vol. 195: 127-132.	
	MARELLI, et al. "Satellite cell implantation for neomyocardial regeneration", <i>Transplantation Proceedings</i> , (1992) Vol. 24(6): 2995.	
	MENASCHÉ, et al. "Myoblast transplantation for heart failure", <i>Lancet</i> , (2001) Vol. 357: 279-280.	
	MURRAY, et al. "Skeletal myoblast transplantation for repair of myocardial necrosis", <i>J Clin Invest</i> , (1996) Vol. 98(11): 2512-2523.	
	Murry, et al., "Muscle Cell Grafting for the Treatment and Prevention of Heart Failure" <i>J. of Cardiac Failure</i> Vol. 8 n0.6 Suppl (2002)	
	MYERBURG, et al. "Sudden cardiac death: Structure, function, and time-dependence of risk", <i>Circulation</i> . (1992) Vol. 85(1): I2-I10.	
	NICHOLAS et al., "Immunocytochemical Analysis of Connexin Expression in the Healthy and Diseased Cardiovascular System", <i>Microscopy Res. Technique</i> . 2001, Vol. 52, pages 301-322	
	ORLIC, et al. "Bone marrow cells regenerate infarcted myocardium", <i>Nature</i> , (2001) Vol. 410: 701-705.	
	PESCHANSKI, et al. "Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon", <i>Brain</i> , (1994) Vol. 117: 487-499.	
	PFEFFER, et al. "Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction", <i>New England J. of Med.</i> , (1988) Vol. 319: 80-86.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/519,128		
		Filing Date	Not yet assigned		
		First Named Inventor	LEE, RANDALL J.		
		Group Art Unit	Not yet assigned		
		Examiner Name	Not yet assigned		
Sheet	5	of	6	Attorney Docket Number	UCAL-253US1

	RAJNOCH, et al. "Cellular therapy reverses myocardial dysfunction", <i>J. Thoracic Cardiovascular Surgery</i> , (2001) Vol. 121(5): 871-878.	
	REINECKE, et al. "Electromechanical coupling between skeletal and cardiac muscle: Implications for infarct repair", <i>J. Cell Biol.</i> , (2000) Vol. 149(3): 731-740.	
	REINECKE, et al. "Transmural replacement of myocardium after skeletal myoblast grafting into the heart: Too much of a good thing?" <i>Cardiovasc Pathol.</i> , (2000) Vol. 9(6): 337-344.	
	ROBINSON, et al. "Arterial delivery of genetically labeled skeletal myoblasts to the murine heart: Long-term survival and phenotypic modification of implanted myoblasts", <i>Cell Transplantation</i> , (1996) Vol. 5(1): 77-91.	
	Suzuki et al, "Overexpression of connexin 43 in skeletal myoblasts: relevance to cell transplantation to the heart", <i>The Journal of Thoracic and Cardiovascular Surgery</i> , 2001, vol. 122, no. 4, pgs. 759-766	
	SCORSIN, et al. "Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function", <i>J Thoracic Cardiovascular Surgery</i> , (2000) Vol. 119: 1169-1175.	
	SOONPA, et al. "Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium", <i>Science</i> , (1994) Vol. 264: 98-101.	
	SPRINGER, et al. "VEGF gene delivery to muscle: Potential role for vasculogenesis in adults", <i>Molecular Cell.</i> , (1998) Vol. 2: 549-558.	
	SPRINGER, et al. "High-efficiency retroviral infection of primary myoblasts", <i>Cell Mol. Genet.</i> , (1997) Vol. 23 (3): 203-209.	
	SUZUKI, et al. "Overexpression of connexin 43 in skeletal myoblasts: Relevance to cell transplantation to the heart", <i>J. Thoracic and Cardiovascular Surgery</i> , (2001) Vol. 122(4): 759-766.	
	TAM, et al. "Molecular cardiomyoplasty: Potential cardiac gene therapy for chronic heart failure", <i>J. of Thoracic and Cardiovascular Surgery</i> , (1995): Vol. 109(5): 918-924.	
	TAYLOR, et al. "Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation", <i>Nature Medicine</i> , (1998) Vol. 4(8): 929-933.	
	TAYLOR, et al. "Delivery of primary autologous skeletal myoblasts into rabbit heart by coronary infusion: A potential approach to myocardial repair", <i>Proceedings of the Association of American Physicians</i> , (1997) Vol. 109:245-253.	
	TREMBLAY, et al. "Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy", <i>Cell Transplantation</i> , (1993) Vol. 2: 99-112.	
	VERHEULE, et al. "Characterization of gap junction channels in adult rabbit atrial and ventricular myocardium", <i>Cir. Res.</i> , (1997) Vol. 80: 673-681.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign (+) inside this



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/519,128
				Filing Date	Not yet assigned
				First Named Inventor	LEE, RANDALL J.
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	6	of	6	Attorney Docket Number	UCAL-253US1

		WEISEL, et al. "Cell transplantation comes of age", <i>J Thoracic Cardiovascular Surgery</i> , (2001) Vol. 121(5): 835-836.	
		YANG et al. VEGF Enhances Functional Improvement of Postinfarcted Hearts By Transplantation of ESC-Differentiated Cells. <i>J. Appl. Physiol.</i> 2002, Vol. 93, pages 1140-1151	
		ZWIEBEL, et al. "Drug delivery by genetically engineered cell implants", <i>Annals of the New York Academy of Sciences</i> , (1991) Vol. 618: 394-404.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.